MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Venetoclax

CAS No. : 1257044-40-8

MCE 国际站：Venetoclax

产品活性：Venetoclax (ABT-199; GDC-0199) 是一种高效，有选择性和口服有效的 Bcl-2 抑制剂，K_i 小于0.01 nM。Venetoclax 可以诱导自噬 (autophagy) 作用。

研究领域：Apoptosis  |  Autophagy

作用靶点：Bcl-2 Family  |  Autophagy

In Vitro: Venetoclax (ABT-199) potently kills FL5.12-BCL-2 cells (EC₅₀=4 nM), Venetoclax (ABT-199) shows much weaker activity against FL5.12-BCL-XL cells (EC₅₀=261 nM). ABT-199 also shows selectivity in cellular mammalian two-hybrid assays, where it disrupts BCL-2-BIM complexes (EC₅₀=3 nM) but is much less effective against BCL-XL-BCL-XS (EC₅₀=2.2 μM) or MCL-1-NOXA complexes.

In Vivo: After a single oral dose of 12.5 mg per kg body weight in xenografts derived from RS4;11 cells (ALL), Venetoclax (ABT-199) causes a maximal tumor growth inhibition (TGI_max) of 47% (P<0.001) and tumor growth delay (TGD) of 26% (P<0.05).
Treatment of established xenografted (a mouse xenograft model of the T-ALL cell line LOUCY) tumors with Venetoclax (ABT-199) 100 mg/kg for 4 days results in a significant reduction of leukemic burden.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Peptidomimetic Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Anti-diabetic Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  Chemical Probe Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Targeted Therapy Drug Library   |  Mitochondria-Targeted Compound Library  |  Targeted Diversity Library  |  Rare Diseases Drug Library  |  Protein-protein Interaction Inhibitor Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Mitochondrial Toxicity Compound Library  |  Highly Selective Inhibitors Library  |  Highly Selective Activators Library  |  Cell Death Library  |  Anti-Hematopathy Compound Library  |  Anti-Ovarian Cancer Compound Library  |  Multi-Target Compound Library  |  Mitophagy Compound Library  |  Bioactive Compound Library Max  |  Navitoclax  |  Polyinosinic-polycytidylic acid  |  Sulforaphane  |  S63845  |  ABT-737  |  A-1331852  |  Chlorin e6  |  Aflatoxin B1  |  BAI1  |  BT2  |  A-1155463  |  AZD-5991  |  Amantadine  |  Estradiol benzoate  |  MIK665  |  Obatoclax Mesylate  |  Benzbromarone  |  Digitoxin  |  BI-3802  |  WEHI-539 hydrochloride  |  Chelerythrine chloride  |  Dehydrocorydaline  |  DT2216  |  AZD4320  |  A-1210477  |  Gambogic Acid  |  Daphnetin  |  Gossypol  |  Tapotoclax  |  Bax inhibitor peptide V5

热门产品线：重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。